The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $110,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Sydney, doing business as the International Clinical Trials Symposium. The funding supports research to delineate the viro-immunological factors contributing to transient HIV control during consecutive analytical treatment interruptions (ATIs). The project aims to extend an existing analysis of full-length HIV sequencing from participants who experienced transient viral control during consecutive ATIs and compare the HIV-specific CD8 T cell response in transient controllers and non-controllers. This research seeks to determine if consecutive ATIs enhance viral and immunological mechanisms contributing to transient viral control, with the goal of identifying strategies to achieve virological remission following antiretroviral therapy discontinuation. The award period is from July 2024 to May 2026.
Generated 3/4/25, 5:12 AM